Sonic Healthcare (ASX:SHL) is set to acquire US pathology services company, Aurora Diagnostics for US$540 million.
The acquisition will be funded by a A$600 million fully underwritten institutional placement as well as a fully underwritten bridge facility.
The company says the purchase will transform its US business, providing it with a strategic national footprint and platform that adds significant scale )and extends Sonic's existing presence in anatomical pathology.
Sonic expects the acquisition to be about 3 per cent EPS accretive post-placement on a pro-forma FY19 basis (before any revenue and cost synergies)
Shares in Sonic Healthcare (ASX:SHL)
are currently in a trading halt and last traded at $21.39.